Effective Chemotherapy of Lung Cancer Using Bovine Serum Albumin-Coated Hydroxyapatite Nanoparticles

• Published in: Medical science monitor 2020-05, Vol.26, p.e919716-e919716-8
• Main Authors: Li, Gongzhuo, Tang, Dongxin, Wang, Dingxue, Xu, Chuan, Liu, Di
• Format: Article
• Language: English
• Subjects: A549 Cells; Animal Study; Antineoplastic Agents - pharmacology; China; Doxorubicin - pharmacology; Drug Carriers - administration & dosage; Drug Delivery Systems - methods; Durapatite - administration & dosage; Humans; Lung Neoplasms - drug therapy; Nanoparticles - administration & dosage; Serum Albumin, Bovine - administration & dosage
• ISSN: 1643-3750; 1234-1010; 1643-3750
• DOI: 10.12659/MSM.919716

BACKGROUND Successful chemotherapy of lung cancer relies largely on the use of a good drug delivery system (DDS). We successfully constructed a hybrid DDS comprised of hydroxyapatite (HAP) nanoparticles and bovine serum albumin (BSA). MATERIAL AND METHODS The HAP nanoparticles were selected as the core to encapsulate the anticancer drug doxorubicin (DOX), followed by surface modification of BSA as a stabilizer and shielding corona to finally prepare the hybrid DDS (BSA/HAP/DOX). RESULTS The following characterizations revealed that BSA/HAP nanoparticles have high stability, high biocompatibility, and good DOX-loading capability to meet in vivo applications. Moreover, BSA/HAP/DOX can enhance the cellular uptake of drug in A549 cells (lung cancer cells). Most importantly, BSA/HAP had better in vivo tumor targetability than bare HAP nanoparticles, which resulted in stronger anticancer efficacy both in vitro and in vivo than free DOX or HAP/DOX, and greatly decreased the adverse effects of free DOX. CONCLUSIONS Our hybrid DDS shows potential to be applied in more advanced application of cancer therapy.